Tandem Diabetes Care reports developments in automated insulin delivery and diabetes technology. The company manufactures and sells pump systems including Tandem Mobi and the t:slim X2 insulin pump, both powered by Control-IQ+ advanced hybrid closed-loop technology. News commonly covers FDA clearances, pump and mobile-app compatibility, continuous glucose monitoring integrations, and product portfolio updates for people with diabetes.
Company updates also address quarterly and annual operating results, worldwide and U.S. sales trends, pump shipments, gross margin, financial guidance, reimbursement-model changes, investor conference presentations, and capital actions such as convertible debt financing.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) showcased successful real-world use data of its t:slim X2™ insulin pump with Control-IQ™ technology at the ATTD conference. Over 9,000 users experienced significant improvements in time in range (TIR) for diabetes management over 12 months. Dr. Jordan Pinsker emphasized the technology's real-world effectiveness and the positive impact on patients' quality of life. Additional studies indicated a median TIR of 73.6%, with high automation rates and low incidences of hypoglycemia, reflecting strong performance and user satisfaction with the device.
Tandem Diabetes Care, Inc. (TNDM) reported a strong first quarter of 2021, with worldwide pump shipments increasing 46% to 25,352 units and sales rising 44% to $141 million, compared to Q1 2020. Gross profit improved to $73.3 million, and Adjusted EBITDA reached $13.2 million. The company's net loss narrowed to $5 million from $14.9 million year-over-year. Tandem updated its 2021 sales guidance, now estimating $625-$640 million, marking a growth of 25-28% year-over-year. International sales are projected at $125-$130 million, reflecting a 50-56% increase.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced its participation in three upcoming virtual investor conferences. Management will provide updates during:
- BofA Securities 2021 Virtual Health Care Conference on May 12, 2021, at 5:00 PM ET
- Berenberg Conference USA 2021 on May 18, 2021, at 3:00 PM ET
- UBS Global Healthcare Virtual Conference on May 24, 2021, at 12:00 PM ET
These presentations will be webcast live and available for 30 days on the company's Investor Center website.
CeQur has completed an oversubscribed $115 million equity financing to support commercial plans for its insulin-delivery device, CeQur Simplicity. The funds will enhance market development, initiate a phased launch in 2021, and scale manufacturing. CeQur Simplicity is FDA cleared and CE-marked, designed to replace multiple daily injections for over 3 million Americans. Clinical studies show significant improvement in insulin regimen adherence and glycemic control. The device targets a $7.5 billion U.S. market, aiming to ease insulin delivery for diabetes patients globally.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is set to release its first quarter 2021 results after market close on May 5, 2021. A conference call will follow at 4:30 PM ET to discuss the financial and operational results. Shareholders and interested parties can access details via dial-in numbers or through a live webcast. Tandem Diabetes is known for its innovative insulin delivery solutions, particularly the t:slim X2™ insulin pump that features remote software updates and integrated continuous glucose monitoring.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced management will present a company update at two upcoming virtual investor conferences. The presentations are scheduled for the Barclays Global Healthcare Conference on March 10, 2021, at 3:00 PM ET and the Oppenheimer’s 31st Annual Healthcare Conference on March 17, 2021, at 2:30 PM ET. The updates will be webcast live, with an archive available for 30 days on Tandem's Investor Center website. This showcases Tandem's commitment to transparency and engagement with investors.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has appointed Jordan Pinsker, MD, as Vice President and Medical Director, effective April 26, 2021. Dr. Pinsker, a renowned pediatric endocrinologist, previously led artificial pancreas research at Sansum Diabetes Research Institute, where he directed clinical trials for automated insulin delivery systems. His extensive experience in diabetes care and technology aligns with Tandem's mission to enhance insulin therapy management. The leadership addition aims to drive innovation in closed-loop insulin delivery and improve outcomes for individuals with diabetes.
Tandem Diabetes Care reported strong financial results for Q4 and FY 2020, with worldwide pump shipments increasing 67% to 32,685 and sales rising 55% to $168.1 million compared to Q4 2019. For the full year, sales reached $498.8 million, a 38% increase, while the gross profit improved 34% to $260.5 million. The company anticipates 20-23% sales growth for 2021, estimating revenue between $600 million and $615 million, with a gross margin of approximately 55%.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced upcoming presentations at various virtual investor conferences, highlighting its commitment to innovation in diabetes technology. Key events include the Citi 2021 Healthcare Services Conference on February 25, the SVB Leerink Global Healthcare Conference on February 26, the Raymond James 42nd Annual Institutional Investors Conference on March 1, and the Cowen 41st Annual Healthcare Conference on March 2. Live webcasts will be available, with recordings archived for 30 days on their Investor Center website.
For more information, visit investor.tandemdiabetes.com.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is set to announce its fourth quarter and full year 2020 results on February 24, 2021. The announcement will be followed by a conference call at 4:30 PM ET to discuss financial and operational outcomes. Investors can access the live webcast and find an archived version for 30 days after the event. Tandem is known for its innovative t:slim X2 insulin pump, which features remote software updates and integrated continuous glucose monitoring, emphasizing its commitment to diabetes care improvement.